Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 3—March 2018

Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000–2015

Miranda G. LoutetComments to Author , Jennifer A. Davidson, Tim Brown, Martin Dedicoat, H. Lucy Thomas, and Maeve K. Lalor
Author affiliations: Public Health England, London, UK (M.G. Loutet, J.A. Davidson, T. Brown, H.L. Thomas, M.K. Lalor); Heart of England NHS Foundation Trust, Birmingham, UK (M. Dedicoat); University College London, London (M.K. Lalor)

Main Article

Table 1

Initial drug resistance profiles used to categorize resistance to anti-TB drugs*

Initial drug resistance profile Description of drug-resistance profile†
Drug sensitive Initially sensitive to both isoniazid and rifampin
Isoniazid resistance without MDR TB Initially resistant to isoniazid and sensitive to rifampin
Rifampin resistance without MDR TB Initially resistant to rifampin and sensitive to isoniazid
MDR TB Initially resistant to both isoniazid and rifampin

*MDR, multidrug-resistant; TB, tuberculosis.
†These profiles refer specifically to resistance to isoniazid and/or rifampin, but resistance to other drugs may also be present.

Main Article

Page created: February 15, 2018
Page updated: February 15, 2018
Page reviewed: February 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.